Radiology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Published online before print August 5, 2008, 10.1148/radiol.2483071579
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
2483071579v1
249/1/107    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Saeed, M.
Right arrow Articles by Saloner, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Saeed, M.
Right arrow Articles by Saloner, D.
Related Collections
Right arrowRelated Article
(Radiology 2008;249:107-118.)
© RSNA, 2008

Experimental Studies

MR Assessment of Myocardial Perfusion, Viability, and Function after Intramyocardial Transfer of VM202, a New Plasmid Human Hepatocyte Growth Factor in Ischemic Swine Myocardium1

Maythem Saeed, DVM, PhD, Alastair Martin, PhD, Phillip Ursell, MD, Loi Do, BS, Matt Bucknor, BA, Charles B. Higgins, MD, and David Saloner, PhD

1 From the Departments of Radiology and Biomedical Imaging (M.S., A.M., L.D., M.B., C.B.H., D.S.) and Pathology (P.U.), University of California San Francisco, 513 Parnassus Ave, HSW 207B, San Francisco, CA 94134-0628. Received September 5, 2007; revision requested November 20; revision received January 11, 2008; accepted February 26; final version accepted March 13. Supported by a grant (R01HL7295) from the National Institutes of Health (M.S.) and a gift from ViroMed, Seoul, South Korea. Address correspondence to M.S. (e-mail: Maythem.Saeed{at}radiology.UCSF.edu).

Purpose: VM202, a newly constructed plasmid human hepatocyte growth factor, was transferred intramyocardially after infarction for the purpose of evaluating this strategy as a therapeutic approach for protection from left ventricular (LV) remodeling.

Materials and Methods: The institutional animal care and use committee approved this study. Pigs underwent coronary artery occlusion and reperfusion and served as either control (n = 8) or VM202-treated (n = 8) animals. VM202 was transferred intramyocardially into four infarcted and four periinfarcted sites. Cardiac magnetic resonance (MR) imaging (cine, perfusion, delayed enhancement) was performed in acute (3 days) and chronic (50 days ± 3 [standard error of the mean]) infarction. Histopathologic findings were used to characterize and quantify neovascularization. The t test was utilized to compare treated and control groups and to assess changes over time.

Results: In acute infarction, MR imaging estimates of function, perfusion, and viability showed no difference between the groups. In chronic infarction, however, VM202 increased maximum signal intensity and upslope at first-pass perfusion imaging and reduced infarct size at perfusion and delayed-enhancement imaging. These changes were associated with a decrease in end-diastolic (2.15 mL/kg ± 0.12 to 1.73 mL/kg ± 0.10, P < .01) and end-systolic (1.33 mL/kg ± 0.07 to 0.92 mL/kg ± 0.08, P < .001) volumes and an increase in ejection fraction (38.2% ± 1.3 to 47.0% ± 1.8, P < .001). In contrast, LV function deteriorated further in control animals. Compared with control animals, VM202-treated animals revealed peninsulas and/or islands of viable myocardium in infarcted and periinfarcted regions and greater number of capillaries (218 per square millimeter ± 19 vs 119 per square millimeter ± 17, P < .05) and arterioles (21 per square millimeter ± 4 vs 3 per square millimeter ± 1, P < .001).

Conclusion: Intramyocardial transfer of VM202 improved myocardial perfusion, viability, and LV function.

© RSNA, 2008


Related Article

Can MR Imaging Be Used to Determine the Efficacy of Gene Therapy in the Heart?
Robert R. Edelman
Radiology 2008 249: 1-2. [Full Text] [PDF]